SIGA Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)

SIGA Technologies, Inc. (NASDAQ:SIGA) was the recipient of unusually large options trading on Wednesday. Stock traders purchased 1,200 call options on the stock. This represents an increase of 1,438% compared to the typical volume of 78 call options.

SIGA Technologies Stock Up 0.9 %

NASDAQ:SIGA opened at $5.88 on Thursday. The firm has a market cap of $419.83 million, a PE ratio of 4.90 and a beta of 0.94. SIGA Technologies has a 12 month low of $4.39 and a 12 month high of $12.83. The company’s 50-day moving average price is $6.28 and its two-hundred day moving average price is $7.36.

SIGA Technologies (NASDAQ:SIGA) last announced its earnings results on Thursday, November 7th. The company reported $0.02 EPS for the quarter. The business had revenue of $10.01 million for the quarter. SIGA Technologies had a return on equity of 49.06% and a net margin of 49.33%. On average, research analysts expect that SIGA Technologies will post 1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On SIGA Technologies

A number of hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC bought a new stake in shares of SIGA Technologies during the third quarter valued at approximately $30,000. EP Wealth Advisors LLC acquired a new stake in SIGA Technologies in the third quarter worth about $82,000. XTX Topco Ltd bought a new stake in SIGA Technologies during the 3rd quarter worth about $85,000. China Universal Asset Management Co. Ltd. raised its holdings in SIGA Technologies by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,727 shares of the company’s stock worth $93,000 after purchasing an additional 5,372 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in SIGA Technologies during the 2nd quarter valued at about $99,000. Institutional investors own 55.40% of the company’s stock.

About SIGA Technologies

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.